Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01715909 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
A Phase 1 study of Influenza, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT01715909 is a Phase 1 study of Influenza that has completed, run by Hoffmann-La Roche. The registered enrollment target is 20 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01715909, a Phase 1 study of Influenza, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (\<) 13 years of age, with confirmed influenza infection. Participants will be randomized to receive either the standard dose or triple dose of oseltamivir orally daily for a minimum of 5 days and up to 20 days. Infants \<1 year of age will be randomized to the standard dose arm only.
Conditions Studied
Interventions
- DRUG Oseltamivir
Study Locations (20)
Other
- UZ Brussel - Brussels
- Cliniques Universitaires St-Luc - Brussels
- UZ Leuven Gasthuisberg - Leuven
- Hospital Dr. Gustavo Fricke - Viña del Mar
- Centro Medico Imbanaco - Cali
- Fundacion Clinica Valle de Lili, Department Rheumatology - Cali
São Paulo
- Graacc-Grupo de Apoio ao adolescente e a crianca com cancer - São Paulo
- Casa de Saúde Santa Marcelina - São Paulo
Ontario
- Children'S Hospital of Eastern Ontario - Ottawa
- Hospital For Sick Children; Infectious Disease Dept - Toronto
California
- Lucile Packard Child Hosp; Pediatric Pulmonary Division - Palo Alto
Colorado
- The Children's Hospital; Pediatric Infectious Diseases - Aurora
Massachusetts
- Tufts Medical Center - Boston
Minnesota
- University of Minnesota - Minneapolis
New York
- SUNY Upstate Medical University - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-01-22 |
| Est. Completion | 2018-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01715909
The ClinicalTrials.gov registry entry for NCT01715909 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Oseltamivir is the first listed.
NCT01715909 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, São Paulo, Ontario.
Frequently Asked Questions
What is clinical trial NCT01715909 about?
NCT01715909 is a clinical study titled "A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection". This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (\<) 13 years of age, with confirmed influenza infection. Participants will be randomized to receive either the st...
What is the current status of trial NCT01715909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-01-22. Estimated completion is 2018-06-17.
What conditions does trial NCT01715909 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01715909?
The interventions under investigation include: Oseltamivir (DRUG).
Who is sponsoring clinical trial NCT01715909?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01715909 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.